Table 2.

Demographic and disease activity measures at baseline and at 52 weeks

	COBRA-light (n=81)	COBRA (n=81)	p Value
Demographics at baseline
Female, n (%)	58 (69)	54 (66)	0.66
Age, years	51 (12)	53 (13)	0.44
Disease duration, months	24 (22)	21 (17)	0.36
EQ-5D	54.2 (20.0)	53.8 (20.0)	0.92
HAQ	1.4 (0.7)	1.4 (0.7)	0.87
Patient global assessment, by VAS, mm	58.3 (25.3)	60.5 (21.9)	0.55
Disease activity and response at week 52
EQ-5D	71.9 (19.3)	74.8 (15.0)	0.31
HAQ	0.61 (0.6)	0.57 (0.5)	0.71
Patient global assessment, by VAS, mm	28.8 (26.2)	31.2 (26.2)	0.57
ACR/Boolean remission	14 (17)	12 (15)	0.72
EULAR response, n (%)
Non-responders	5 (6)	5 (6)	0.97
Good responders	49 (60)	56 (69)	0.18
ACR response, n (%)
ACR non-responders	20 (25)	19 (23)	0.89
ACR70	28 (35)	25 (31)	0.65

Data are expressed as mean (SD) unless otherwise stated.

ACR, American College of Rheumatology; anti-CCP, anticyclic citrullinated peptide; COBRA, COmbinatie therapie Bij Reumatoïde Artritis; EULAR, European League against Rheumatism; EQ-5D, EuroQol 5 Dimensions; HAQ, Health Assessment Questionnaire; VAS, visual analogue scale.